Arsenijevic Tatjana, Nicolle Remy, Bouchart Christelle, D'Haene Nicky, Demetter Pieter, Puleo Francesco, Van Laethem Jean-Luc
Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.
Department of Gastroenterology, Hepatology and Digestive Oncology, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.
Cancers (Basel). 2021 Mar 11;13(6):1231. doi: 10.3390/cancers13061231.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal types of cancer with a dismal prognosis. The five-year survival rate has not changed significantly in over 40 years. Current first-line treatments only offer a modest increase in overall survival in unselected populations, and there is an urgent need to personalize treatment in this aggressive disease and develop new therapeutic strategies. Evolving evidence suggests that the human microbiome impacts cancerogenesis and cancer resistance to therapy. The mechanism of action and interaction of microbiome and PDAC is still under investigation. Direct and indirect effects have been proposed, and the use of several microbiome signatures as predictive and prognostic biomarkers for pancreatic cancer are opening new therapeutic horizons. In this review, we provide an overview for the clinicians of studies describing the influence and associations of oral, gastrointestinal and intratumoral microbiota on PDAC development, progression and resistance to therapy and the potential use of microbiota as a diagnostic, prognostic and predictive biomarker for PDAC.
胰腺导管腺癌（PDAC）仍然是最致命的癌症类型之一，预后很差。40多年来，其五年生存率没有显著变化。目前的一线治疗仅能使未经过选择的人群的总生存期略有增加，在这种侵袭性疾病中迫切需要个性化治疗并开发新的治疗策略。越来越多的证据表明，人类微生物群会影响癌症发生和癌症对治疗的抵抗性。微生物群与PDAC的作用机制和相互作用仍在研究中。已经提出了直接和间接影响，并且使用几种微生物群特征作为胰腺癌的预测和预后生物标志物正在开启新的治疗前景。在这篇综述中，我们为临床医生概述了一些研究，这些研究描述了口腔、胃肠道和肿瘤内微生物群对PDAC发生、发展和治疗抵抗性的影响及关联，以及微生物群作为PDAC诊断、预后和预测生物标志物的潜在用途。
